Thea Eline Hetland
Position: Residence physician, MD
Phone: +47 22 93 47 71
Email:
 

Publications 2013

Sioud M, Saebøe-Larssen S, Hetland TE, Kaern J, Mobergslien A, Kvalheim G (2013)
Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients
Int J Oncol, 43 (1), 280-8
PubMed 23620105

Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF (2013)
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Hum Pathol, 44 (9), 1859-66
PubMed 23656974

Publications 2012

Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B (2012)
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
PubMed 22476403

Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA (2012)
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
PubMed 22302409

Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B (2012)
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
PubMed 22652154

Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B (2012)
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
PubMed 23114921

Vaksman O, Hetland TE, Trope' CG, Reich R, Davidson B (2012)
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
Hum Pathol, 43 (11), 2062-9
PubMed 22647351

Publications 2011

Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B (2011)
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
Hum Pathol, 43 (4), 496-505
PubMed 21855111

Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Piek JM, Manchanda R, Grimm C, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Steffensen KD, Gristsenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Tsolakidis D, Novak Z et al. (2011)
Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists
Int J Gynecol Cancer, 21 (8), 1500-6
PubMed 21720256

Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J (2011)
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
PubMed 21315408

Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC (2011)
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
Cancer, 118 (6), 1543-53
PubMed 22009736

Publications 2008

Andersen HB, Holm M, Hetland TE, Dahl C, Junker S, Schiøtz PO, Hoffmann HJ (2008)
Comparison of short term in vitro cultured human mast cells from different progenitors - Peripheral blood-derived progenitors generate highly mature and functional mast cells
J Immunol Methods, 336 (2), 166-74
PubMed 18538784

Holm M, Andersen HB, Hetland TE, Dahl C, Hoffmann HJ, Junker S, Schiøtz PO (2008)
Seven week culture of functional human mast cells from buffy coat preparations
J Immunol Methods, 336 (2), 213-21
PubMed 18547584